论文部分内容阅读
将64例恶性血液病化疗后合并严重感染的患者,随机分为3组抗感染治疗:泰能(Tienam)组,头孢他啶(CAZ)组和环丙沙量(CPLX)组.泰能组的有效率为86.4%,明显高于CAZ组(有效率 71.5%,P<0.05)和 CPLX组(有效率57.0%,P<0.01),与CAZ或CPLX联合去甲万古霉素的疗效相仿.同时体外抗菌活性试验显示,泰能对金葡菌、表皮葡萄球菌的最低抑菌浓度(MIC90)为 0.25mg/L,敏感率100%,敏感率明显高于CAZ(P<0.001);泰能对绿脓杆菌的MIC90为4mg/L,敏感率84.9%,明显高于CPLX(P<0.01),大肠杆菌、肺炎杆菌对3种抗生素的敏感度差异无显著性(P>0.05),泰能的抗菌活性最强,抗菌谱最广,这与临床疗效相符.
Sixty-four patients with severe hematologic malignancies complicated with chemotherapy were randomly divided into three groups of anti-infective treatments: the Tienam group, the ceftazidime (CAZ) group, and the ciprofloxacin (CPLX) group. The efficiency was 86.4%, which was significantly higher than that of CAZ group (effective rate 71.5%, P<0.05) and CPLX group (effective rate 57.0%, P<0.01). The efficacy of norvancomycin combined with CAZ or CPLX was similar. The antibacterial activity test showed that the minimum inhibitory concentration (MIC90) of Tygon against Staphylococcus aureus and Staphylococcus epidermidis was 0.25 mg/L, the sensitivity rate was 100%, and the sensitivity rate was significantly higher than that of CAZ (P<0.001); The MIC90 of A.s.ae was 4 mg/L, and the sensitivity rate was 84.9%, which was significantly higher than that of CPLX (P<0.01). The sensitivity of E. coli and K. pneumoniae to the three antibiotics was insignificant (P>0.05). The strongest activity, the broadest antibacterial spectrum, which is consistent with the clinical efficacy.